Ongoing open-label extension trials of simufilam in Alzheimer’s disease to be extended by up to an additional 36 months. The extension provides participants the opportunity to continue on treatment, ...
Bristol-Myers Squibb Company ($BMY) announced an update on their ongoing clinical study. Study Overview: Bristol-Myers Squibb ...
Phase 1b data shows treatment with SAT-3247 was safe and well-tolerated Pharmacokinetic (PK) profile of SAT-3247 translated as expected to Duchenne Muscular Dystrophy (DMD) patients taking concurrent ...
Pfizer Inc ($PFE) announced an update on their ongoing clinical study. PFE’s New Liver Cancer Trial: Early Signal to Watch The study, officially ...
-- 80% or greater reduction in metastatic breast cancer recurrence rate over 5 years of follow-up with a peak immune response at 6 months and well-tolerated safety profile. -- The PIS elicited a ...
Abemaciclib Plus Fulvestrant in Advanced Breast Cancer After Progression on CDK4/6 Inhibition: Results From the Phase III postMONARCH Trial Patients with stage III to IV or recurrent, radiographically ...
Cassava Sciences (NASDAQ:SAVA) is extending ongoing open-label extension trials of its lead drug candidate, simufilam, in Alzheimer’s disease by up to an additional 36 months. “Cassava Sciences will ...
Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the 'Company'), a clinical-stage biopharmaceutical company focused on its Phase ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback